

Probing the Role of Backbone Hydrogen Bonding in a Critical β Sheet of the Extracellular Domain of a Cys-Loop Receptor

Kristin R. Gleitsman,^[a] Henry A. Lester,^[b] and Dennis A. Dougherty^{*[a]}

Long-range communication is essential for the function of members of the Cys-loop family of neurotransmitter-gated ion channels. The involvement of the peptide backbone in binding-induced conformational changes that lead to channel gating in these membrane proteins is an interesting, but unresolved issue. To probe the role of the peptide backbone, we incorporated a series of α -hydroxy acid analogues into the β -sheet-rich extracellular domain of the muscle subtype of the nicotinic acetylcholine receptor, the prototypical Cys-loop receptor. Specifically, mutations were made in β strands 7 and 10

of the α subunit. A number of single backbone mutations in this region were well tolerated. However, simultaneous introduction of two proximal backbone mutations led to surface-expressed, nonfunctional receptors. Together, these data suggest that while the receptor is remarkably robust in its ability to tolerate single amide-to-ester mutations throughout these β strands, more substantial perturbations to this region have a profound effect on the protein. These results support a model in which backbone movements in the outer β sheet are important for receptor function.

Introduction

An essential feature of allosteric proteins is that they are innately dynamic molecules, with the Cys-loop superfamily of ligand-gated ion channels providing a classic example. These neurotransmitter receptors are involved in mediating fast synaptic transmission throughout the central and peripheral nervous systems.^[1–5] They are among the molecules of learning, memory, and sensory perception, and they are implicated in numerous neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The muscle subtype of the nicotinic acetylcholine receptor (nAChR) is the prototypical Cys-loop receptor. It is a pentamer of homologous subunits arranged pseudo-symmetrically around a central ion-conducting pore. The extracellular domain largely consists of β -sheet structure and contains the agonist binding site. The agonist binding site itself is shaped by discontinuous flexible loop regions that meet at the interface between subunits. The primary contributors to the agonist binding site are in the α subunit, with additional contributions from the complementary subunits (γ and δ). The transmembrane domain of each subunit is made up of four membrane-spanning α helices, with one from each subunit lining the pore. Binding of a small-molecule agonist in the extracellular domain triggers a series of conformational changes that leads to the opening of the channel gate some 60 Å away.

Long-range communication is clearly critical in the function of these receptors.^[6,7] Various models for how this communication occurs have been proposed, from specific side chain interactions to more rigid large-scale domain movements.^[8–11] Recent linear free-energy analysis of the nAChR has given rise to the notion of a "conformational wave"^[8] that emanates from the agonist binding site to the gate of the channel in the transmembrane domain. It seems likely that some movement

must occur in the immediate region of the binding interaction, with simple side chain movements making up only a part of the ensuing conformational wave. Significant movements along the peptide backbone may also play a critical role in the initiation of channel gating.

To investigate the involvement of the peptide backbone in binding-induced conformational changes that lead to channel gating, we incorporated a series of α -hydroxy acid analogues into the β -sheet-rich extracellular domain of the nAChR (Figure 1). Upon incorporation of an α -hydroxy acid into a protein, the backbone amide functional group is replaced by an ester, with two major consequences (Scheme 1). First, the ester bond disrupts the backbone hydrogen bonding pattern associated with β -sheet structure. The ester lacks the NH hydrogen bond donor, and the ester carbonyl is a weaker hydrogen bond acceptor than the amide carbonyl. Previous studies on a small three-stranded β -sheet protein found that the effect of weakening a hydrogen bond acceptor (the carbonyl) is less destabilizing than removing the hydrogen bond donor (the NH) by about 0.8 kcal mol^{−1}.^[12] Second, while the *s-trans* planar conformational preference, bond lengths, and bond angles are generally similar to those of amide bonds, the ester bond possesses much greater backbone flexibility due to a substantial

[a] K. R. Gleitsman, Dr. D. A. Dougherty
Division of Chemistry and Chemical Engineering
California Institute of Technology
1200 E. California Boulevard, Pasadena, CA 91106 (USA)
Fax: (+1) 626-564-9297
E-mail: dadougherty@caltech.edu

[b] Dr. H. A. Lester
Division of Biology, California Institute of Technology
1200 E. California Boulevard, Pasadena, CA 91106 (USA)





Figure 1. Two views of the nAChR. A) Overall layout of the receptor. One of the five subunits is shown in blue, with $\beta 7$, $\beta 9$, and $\beta 10$ highlighted in red, yellow, and green, respectively. B) The hydrogen bonding network of the outer β sheet of the nAChR. Turquoise balls indicate the positions at which the backbone NH was mutated to an oxygen atom. The black dashed lines indicate hydrogen bonds that are completely removed or attenuated as a result of mutation. The image is based on the cryoelectron micrograph of the full Torpedo receptor (PDB ID: 2BG9).^[18]

decrease in the rotation barrier around the C–O versus the C–N single bond.

In the present work, amide-to-ester mutations were made in two critical β strands that connect the agonist binding site to the transmembrane region of the receptor (Figure 1). To our

knowledge, this is the first systematic study of amide-to-ester mutations in a β sheet of a large allosteric receptor. Specifically, mutations were made in β strands 7 and 10 ($\beta 7$ and $\beta 10$, respectively) of the α subunit, and found to disrupt the extensive backbone hydrogen bonding network in what has been termed the outer β sheet of the extracellular domain. The rationale behind studying these strands was twofold. First, $\beta 7$ connects the critical cation– π binding residue in loop B (α W149)^[13] to the eponymous Cys-loop, which directly contacts the transmembrane region. The $\beta 10$ extends from loop C, which contains two other aromatic binding box residues,^[14,15] and connects directly to the first transmembrane helix. Second, recent studies strongly implicate the outer β sheet in connecting agonist binding to channel gating.^[10,16–19] A study of $\beta 7$ and $\beta 10$ in the neuronal $\alpha 7$ nAChR suggests that the rigidity of this region is crucial in transducing channel gating.^[17] Furthermore, previous studies show that a triad of residues in this region is important in initiating channel gating.^[10] These residues are the C-loop residue α Y190, along with α K145 and α D200, on $\beta 7$ and $\beta 10$, respectively. Thus, it seemed reasonable to assume that the outer β sheet was important for connecting agonist binding to channel gating, and that backbone dynamics and hydrogen bonding might be in-



Scheme 1. Schematic representation of the backbone amide versus the backbone ester bond in the context of a β sheet.

volved. Given that the balance between rigidity and flexibility is believed to be central to the structure and function of allosteric proteins,^[7] involvement of the peptide backbone in mediating allosteric communication in the nAChR would not be surprising. Previous studies of backbone esters in ion channels have focused on the role of backbone flexibility in α -helical domains,^[20–22] seeking local movements that directly influence channel gating. Here we hope to better understand how hydrogen bonding in a critical β -sheet region that is distal to the channel gate influences receptor function.

Surprisingly, a number of single backbone mutations in this region were well tolerated, producing only modest shifts in EC_{50} and wild-type-like macroscopic current sizes (I_{max}) in the majority of cases. However, simultaneous introduction of two backbone mutations, either in the same β strand separated by a single amino acid or at amino acids sharing a hydrogen bond between the two β strands, led to surface-expressed, nonfunctional receptors. Together, these data suggest that while the receptor is remarkably robust in its ability to tolerate single amide-to-ester mutations throughout these β strands, more substantial perturbations to this region have a profound effect on the protein. Therefore, it would seem that backbone movements in the outer β sheet are important for receptor function. This adds to a growing body of evidence that points to the importance of this region in mediating the conformational changes that emanate from the agonist binding site to the gate of the channel.

Results

Single amide-to-ester mutations in $\beta 7$ and $\beta 10$ have minimal impact on receptor function

Nine α -hydroxy acids were incorporated into $\beta 7$ and $\beta 10$ of the α subunit extracellular domain, perturbing a total of 13 hydrogen bonds (Figure 1). In some cases, the α -hydroxy analogue of the native amino acid was not available. In these instances, conventional mutagenesis was employed to find an alternative amino acid side chain that had both minimal effect on receptor function and an available α -hydroxy analogue. The effect of the amide-to-ester mutation was then compared with the analogous side-chain mutant, instead of the wild-type receptor. Most amide-to-ester mutations produced modest changes in EC_{50} (less than twofold; Figure 2, Table 1). In three cases ($\alpha M144$, $\alpha L199$, and $\alpha V206$) larger, although still not immense, shifts in the 3.5–4-fold range were observed. ACh-induced whole-cell currents of receptors with single α -hydroxy mutations were similar to the currents produced by incorporation of the native amino acid by nonsense suppression.

As EC_{50} is a composite of both binding and gating phenomena, small shifts in EC_{50} may mask a large effect on receptor behavior. Recently, we developed a method to evaluate whether a loss of function (increase in EC_{50}) mutation in the extracellular domain strongly impacts receptor gating (rather than agonist binding).^[23] The method, termed ELFCAR (Elucidating Long-range Functional Coupling in Allosteric Receptors), is based on mutant cycle analysis and produces a value for Ω ,




Figure 2. Characteristics of nAChR with backbone mutations in β strands 7 and 10. A) EC_{50} shifts for backbone mutations made at nine positions in $\beta 7$ and $\beta 10$. Modest effects on receptor function are observed in all cases. B) Current traces for backbone mutations made at nine positions in $\beta 7$ and $\beta 10$.

Table 1. EC_{50} and Hill coefficient values (\pm SEM) for mutations made in this study.

	EC_{50} [μM]	n_H
wild-type	46 ± 2	1.8 ± 0.13
$\alpha M144$ Leu	15 ± 0.3	1.7 ± 0.06
$\alpha M144$ Lah	50 ± 0.8	1.7 ± 0.03
$\alpha L146$ Lah	26 ± 0.8	1.3 ± 0.05
$\alpha T148$ Tah	33 ± 3	1.0 ± 0.06
$\alpha L199$ Lah	11 ± 0.5	1.6 ± 0.10
$\alpha I201$ lah	82 ± 6	1.5 ± 0.12
$\alpha T202$ Tah	24 ± 1	1.4 ± 0.09
$\alpha Y203$ Yah	39 ± 0.8	1.9 ± 0.07
$\alpha F205$ Tyr	90 ± 2	1.5 ± 0.05
$\alpha F205$ Yah	67 ± 62	1.4 ± 0.13
$\alpha V206$ Vah	170 ± 10	1.9 ± 0.20

the coupling between extracellular domain residue and a known gating mutation (in this case β L9'S). This method uses whole-cell data to determine whether a mutant that produces a moderate to large increase in EC_{50} has a substantial impact on receptor gating, as indicated by $\Omega > 2$. ELFCAR is especially valuable in interpreting moderate increases in EC_{50} , where a dramatic effect on gating might otherwise be missed. An Ω value near 1, however, does not preclude a modest effect on gating. The three α -hydroxy mutants in this study that produce increases in EC_{50} —at positions 144, 201, and 206—all produce an Ω value near 1 (0.97, 0.65, and 0.69, respectively), suggesting no dramatic impact on receptor gating. This method is not applicable to gain-of-function mutations, so the remaining six mutants could not be evaluated using ELFCAR. Combined, the data suggest that single α -hydroxy mutations in this region do not substantially impair receptor gating.

Simultaneous incorporation of two α -hydroxy acid mutations in β 7 and β 10 produces non-functional, surface-expressed receptors

The impact of disrupting the polypeptide backbone at more than one location was investigated by simultaneously incorporating two α -hydroxy acids. This was done in two different ways: amide-to-ester mutations were made either in the same β strand separated by a single amino acid (α M144 and α L146 in β strand 7), or at amino acids sharing a hydrogen bond between the two β strands (α L146 and α L201; Figure 1). Simultaneous incorporation of the same α -hydroxy (Lah) or amino (Leu, in the case of wild-type recovery) acid was done in both scenarios. This allowed for double suppression using the standard nonsense suppression methodology (see the Experimental Section). As a large shift in EC_{50} value might have been anticipated, the double mutation experiments were carried out in the presence of the β L9'S gating mutation. For mutations that primarily affect binding or have a only moderate effect on channel gating this mutation lowers the

EC_{50} by about 40-fold, allowing reliable EC_{50} measurement of potentially highly deleterious mutations without complications from open channel block at high agonist concentrations.

For both double-mutation (Lah) experiments, no whole-cell current was observed in response to high ($> 1000 \mu\text{M}$) doses of ACh. Wild-type recovery (Leu) by nonsense suppression gave normal whole-cell currents in the range of 5–15 μA . Lack of an electrophysiological response can indicate that protein folding, subunit assembly, receptor transport, or receptor function have been impacted.

To determine whether nonfunctional mutant receptors were expressed at the plasma membrane, the localization of these mutant receptors was studied using single molecule total in-




Figure 3. Analysis of dysfunctional nAChRs containing two amide-to-ester mutations by TIRF microscopy. A) Puncta density for receptors labeled with Leu refers to recovery of the wild-type peptide backbone by nonsense suppression; Lah refers to incorporation of leucine α -hydroxy; 76-mer indicates the negative control experiment (co-injection of mRNA with a tRNA molecule that has not been charged with an amino or hydroxy acid). The puncta density for both Leu and Lah are significantly higher than that of either the 76-mer or uninjected oocyte controls (t-test values for Lah versus 76-mer are: $P = 0.0009$ (L146I120); $P < 0.0001$ (L146M144); for Lah versus uninjected: $P = 0.0003$ (L146I120); $P < 0.0001$ (L146M144). Data are compiled from ≥ 6 non-overlapping images from ≥ 2 oocytes. B) Representative TIRF images corresponding to the data in (A); scale bar: 6 μm .

ternal reflectance fluorescence (TIRF) microscopy. Mutant and wild-type (recovery by nonsense suppression) receptors were first labeled with biotin conjugated to α -bungarotoxin and subsequently labeled with streptavidin conjugated to the fluorophore Alexa488. Fluorescent puncta corresponding to single receptors were clearly visible on the cell surface (Figure 3B). For the double α -hydroxy-containing receptors, the number of puncta was between 50 and 70% of the value observed for wild-type receptor (recovery by nonsense suppression; Figure 3B, Table 2). Based on previous extensive studies with this

Table 2. Puncta densities and corresponding estimated current sizes from TIRF microscopy experiments.

	# Puncta per image frame	Calculated current size [μ A]
α L201L146		
Leu	265 \pm 36	7.5 \pm 1.0
Lah	179 \pm 33	5.1 \pm 0.9
76-mer	51 \pm 10	1.4 \pm 0.3
uninjected	27 \pm 5	0.8 \pm 0.2
α L146M144		
Leu	214 \pm 15	6.1 \pm 0.4
Lah	121 \pm 4	3.4 \pm 0.1
76-mer ^[a]	56 \pm 5	1.6 \pm 0.1
uninjected	37 \pm 4	1.0 \pm 0.1

[a] 76-mer refers to unaminoacylated tRNA.

approach,^[24] it is clear that double-mutant receptors are surface expressed at a level that would allow significant whole-cell current to be observed, if the receptors were functional. That is, the calculated expected whole-cell currents from the α -hydroxy double-mutant receptors based on puncta density are on the order of 3–5 μ A (Table 2). Because we can easily detect this magnitude of ACh-induced current, our results clearly show that nonfunctional receptors have been expressed on the oocyte surface. The calculated expected whole-cell currents from the wild-type receptors based on puncta density are on the order of 6–7 μ A, in agreement with the electrophysiological data.

Note that α -bungarotoxin is a potent inhibitor of the nAChR that binds tightly in the same region^[25] as ACh and requires properly folded receptor for tight binding. Thus, successful α -bungarotoxin binding indicates that the overall structure of the extracellular domain and binding site were not grossly perturbed. These results indicate that simultaneous incorporation of two α -hydroxy mutations in this region leads to nonfunctional, surface-expressed receptors.

Discussion

The β -sandwich structure consisting of “inner” and “outer” β sheets, first revealed in the AChBP structure^[14,15] and later confirmed in images of the full nAChR,^[18,26] is accepted as a critical structural feature of Cys-loop receptors. In the present work, we probed the robustness of this structure by selectively

removing or weakening backbone hydrogen bonds that define the structure through the use of backbone ester substitution. The remarkable generality of nonsense suppression techniques for incorporating unnatural residues into receptors and channels expressed in *Xenopus* oocytes makes this study possible. One could have imagined several outcomes for such experiments. If movement within the sheets is critical to receptor function, backbone mutations could facilitate receptor gating, perhaps even creating constitutively active receptors. Alternatively, if an intact β sandwich is essential for receptor function, backbone mutations could disable the receptor.

Here we have focused on the outer β sheet of the extracellular domain, and in particular on β 7 and β 10, which have been proposed to play key roles in receptor function. Perhaps surprisingly, individual amide-to-ester mutations throughout both strands resulted in functional receptors with only modest changes in EC₅₀. Evidently, the outer β sheet is relatively robust, and the receptor can absorb the loss of a single hydrogen bond in this region. Interestingly, however, simultaneous replacement of two nearby residues with their α -hydroxy analogues produced surface-expressed, but nonfunctional receptors. Using receptor labeling with fluorescent α -bungarotoxin, and single-molecule imaging by TIRF microscopy, we demonstrate that the number of double-mutant receptors expressed on the oocyte is more than adequate to produce measurable currents, if the receptors were functional. Tight binding by α -bungarotoxin requires proper folding in the region of the agonist binding site, which is quite near the mutations considered here. In fact, in the α -bungarotoxin-bound crystal structure of the α 1 subunit,^[27] residues at the top of both β 7 and β 10 are in close proximity to the bound α -bungarotoxin molecule. Successful binding of α -bungarotoxin to the double-mutant receptors, as detected by TIRF microscopy, strongly suggests that the structure of this region is not greatly perturbed.

The implication is that the crucial outer β sheet of the nAChR is not overly fragile—it can tolerate the disruption caused by a single backbone substitution—but it must be intact for receptor function, and apparently two proximal backbone mutations are too disruptive. Folding, assembly, and transport to the cell surface, however, can still occur in the double mutants discussed herein.

These results can be understood in the context of emerging models of the conformational changes in the extracellular domain that lead to receptor activation. Recent MD simulations^[19,28] have pointed to a pivotal role for β 10 in communicating the inward motion of the agonist binding-site-shaping C-loop to the motions of the transmembrane domain that eventually produce channel opening. The proposed upward and outward motion allows α R209 on β 10 to approach α E45 on the β 2– β 3 linker, resulting in an interaction between these two residues: an interaction that was previously concluded to be important for coupling agonist binding and channel gating based on mutant-cycle analysis of single-channel data.

The β 7 likewise harbors a residue (α K145) that has been implicated in connecting agonist binding with channel gating. When agonist binds and the C-loop closes in, a salt bridge between α K145 on β 7 and α D200 on β 10 breaks, and α K145

forms a hydrogen bond with α Y190 on the C-loop.^[10] This electrostatic rearrangement was proposed to initiate conformational changes that contribute to opening of the central ion-conducting pore.

Studies of engineered disulfide linkages between β 7 and β 10 in the α 7 nAChR also suggest that the outer β sheet plays a role in transmitting agonist binding-induced conformational changes to the channel gate.^[17] Specifically, in the background of a non-desensitizing mutation, one engineered disulfide-containing receptor could be activated by divalent cations alone, which normally play a role as allosteric modulators. This implies that reduced mobility in the outer β sheet of these receptors results in a lower barrier to channel activation. These and other researchers^[16] have suggested that this β sheet may act as a lever, where binding at one end tilts the lever, resulting in a movement at the other, transmembrane-adjacent, end. A certain amount of rigidity in this region seems to be fundamental to normal receptor function.

Using this lever analogy, our results suggest that two or more nearby α -hydroxy acid mutations lead to a more flexible and thus ineffective lever that is unable to communicate agonist binding events to the transmembrane region of the receptor. Thus, disruption of hydrogen bonding in the outer β sheet would seem to interrupt the conformational wave that connects the agonist binding-induced motions of the C-loop to the subsequent motions of the transmembrane region.

It is also possible that the loss of hydrogen bonding between these strands could lead to misalignment of the binding box residues, impairing agonist binding to the receptor. However, it seems less likely that the binding region of the receptor is grossly malformed, as α -bungarotoxin is still able to bind to the mutant receptors.

Conclusions

In conclusion, we find that the network of hydrogen bonds formed in the outer β sheet of the nAChR is fairly robust, tolerating single amide-to-ester mutations throughout. However, eliminating two proximal hydrogen bonds completely destroys receptor function, adding further support to gating models that ascribe important roles to these β strands of the nAChR extracellular domain.

Experimental Section

Unnatural hydroxy acid suppression: Synthetic α -hydroxy acids were conjugated to the dinucleotide dCA and ligated to truncated 74-nucleotide tRNA as previously described.^[29] Typically, tRNA (25 ng) was injected per oocyte along with mRNA in a total volume of 50 nL per cell. The mRNA was prepared by in vitro runoff transcription using the Ambion (Austin, TX) T7 mMessage mMachine kit. The site of interest was mutated to the amber stop codon by standard means, verified by sequencing through both strands. Mouse muscle embryonic nAChR in the pAMV vector was used. A total of 4.0 ng of mRNA was injected in an $\alpha/\beta/\gamma/\delta$ subunit ratio of 10:1:1:1. The ratio of tRNA to mRNA was typically 1:1. In addition, the α subunits contain a hemagglutinin epitope in the M3M4 cytoplasmic loop for Western blot studies. Control experi-

ments show that this epitope does not detectably alter EC_{50} . As a negative control for suppression, truncated 74-nucleotide tRNA or truncated tRNA ligated to dCA to give a 76-mer was co-injected with mRNA in the same manner as fully charged tRNA. Data from experiments in which currents from these negative controls was greater than 10% of the experimental were excluded. The positive control for suppression involved wild-type recovery by co-injection with 74-nucleotide tRNA ligated to wild-type amino acid. For suppression at multiple sites, the tRNA/mRNA ratio was increased to 2:1.

Electrophysiology: Stage V–VI oocytes of *Xenopus laevis* were used. Oocyte recordings were made 12–48 h post-injection in two-electrode voltage clamp mode using the OpusXpress 6000A instrument (Axon Instruments, Union City, CA, USA). Oocytes were superfused with a Ca^{2+} -free ND96 solution at flow rates of 1 mL min⁻¹ before application, (15 s) 4 mL min⁻¹ during drug application, and 3 mL min⁻¹ during wash. Holding potentials were -60 mV. Data were sampled at 125 Hz and filtered at 50 Hz. Acetylcholine chloride was purchased from Sigma–Aldrich/RBI. Solutions ranging from 0.01 to 5000 mM were prepared in Ca^{2+} -free ND96 from a 1 M stock solution. Dose–response data were obtained for a minimum of eight concentrations of agonists and for a minimum of five cells. Dose–response relations were fitted to the Hill equation to determine EC_{50} and Hill coefficient values. The dose–response relations of individual oocytes were examined and used to determine outliers. The reported EC_{50} values are from the curve fit of the averaged data.

Total internal reflection fluorescence microscopy: *Xenopus* oocytes were prepared for single-molecule TIRF microscopy as follows: 24–48 h after injection of mRNA and tRNA, oocytes were incubated in a solution of biotin (0.5 ng μ L⁻¹) conjugated to α -bungarotoxin (Molecular Probes, Invitrogen, Eugene, OR, USA) for 4–12 h. This was followed by two wash steps with a solution of bovine serum albumin (BSA; 5 mg mL⁻¹) and one wash with Ca^{2+} -free ND96. Subsequently, oocytes were incubated in a solution of streptavidin (0.2 ng μ L⁻¹) conjugated to the fluorophore Alexa488 (Molecular Probes, Invitrogen, Eugene, OR, USA) for 15–30 min, followed by two additional wash steps each with BSA and Ca^{2+} -free ND96. The vitelline membrane of labeled oocytes was removed with forceps following incubation (5–10 min) in a hypertonic solution (220 mM sodium aspartate, 10 mM HEPES, 10 mM EDTA, 2 mM MgCl₂, pH 7.38). Devitellinized oocytes were transferred to an imaging chamber with a clean glass cover-slip mounted on the microscope stage with the animal pole oriented toward the cover-slip. The TIRF microscope used to collect the data consists of a Melles-Griot Ar ion laser coupled to a fiber optic that extends to an Olympus TIRF illuminator adapted to a standard inverted IX-71 Olympus microscope (Center Valley, PA, USA). A wavelength of 488 nm was used to excite and detect the Alexa488 fluorophores by using the Z488 filter cube from Chroma Technology Corporation (Rockingham, VT, USA). A 100 \times 1.45 NA Olympus TIRF objective was used. Images were captured with a Photometrics Cascade front illuminated CCD camera from Princeton Instruments (Trenton, NJ, USA). Andor iQ from Andor Technology (South Windsor, CT, USA) was used to acquire the data. The data were subsequently processed and analyzed with ImageJ (National Institutes of Health). Puncta were manually counted, and densities from ≥ 6 images and ≥ 2 oocytes were compiled and averaged. Expected current sizes were calculated as:

$$[(\# \text{ puncta})/(\text{image frame area})] \times (\text{average oocyte area}) \times (\text{single channel conductance}).$$

Acknowledgements

We thank Dr. Rigo Pantoja for advice and assistance with TIRF measurements. This work was supported by the NIH (NS 34407; NS 11756). K.R.G. was partially supported by an NSF Graduate Research Fellowship.

Keywords: allosterism • backbone esters • ion channels • mutagenesis • receptors

- [1] P. J. Corringer, N. Le Novère, J. P. Changeux, *Annu. Rev. Pharmacol. Toxicol.* **2000**, 40, 431.
- [2] T. Grutter, J. P. Changeux, *Trends Biochem. Sci.* **2001**, 26, 459.
- [3] C. N. Connolly, K. A. Wafford, *Biochem. Soc. Trans.* **2004**, 32, 529.
- [4] H. A. Lester, M. I. Dibas, D. S. Dahan, J. F. Leite, D. A. Dougherty, *Trends Neurosci.* **2004**, 27, 329.
- [5] S. M. Sine, A. G. Engel, *Nature* **2006**, 440, 448.
- [6] J. P. Changeux, S. J. Edelstein, *Science* **2005**, 308, 1424.
- [7] Q. Cui, M. Karplus, *Protein Sci.* **2008**, 17, 1295.
- [8] C. Grosman, M. Zhou, A. Auerbach, *Nature* **2000**, 403, 773.
- [9] W. Y. Lee, S. M. Sine, *Nature* **2005**, 438, 243.
- [10] N. Mukhtasimova, C. Free, S. M. Sine, *J. Gen. Physiol.* **2005**, 126, 23.
- [11] X. Xiu, A. P. Hanek, J. Wang, H. A. Lester, D. A. Dougherty, *J. Biol. Chem.* **2005**, 280, 41655.
- [12] S. Deechongkit, P. E. Dawson, J. W. Kelly, *J. Am. Chem. Soc.* **2004**, 126, 16762.
- [13] W. Zhong, J. P. Gollivan, Y. Zhang, L. Li, H. A. Lester, D. A. Dougherty, *Proc. Natl. Acad. Sci. USA* **1998**, 95, 12088.
- [14] K. Brejc, W. J. van Dijk, R. V. Klaassen, M. Schuurmans, J. van Der Oost, A. B. Smit, T. K. Sixma, *Nature* **2001**, 411, 269.
- [15] T. K. Sixma, A. B. Smit, *Annu. Rev. Biophys. Biomol. Struct.* **2003**, 32, 311.
- [16] R. J. Law, R. H. Henchman, J. A. McCammon, *Proc. Natl. Acad. Sci. USA* **2005**, 102, 6813.
- [17] J. T. McLaughlin, J. Fu, A. D. Sproul, R. L. Rosenberg, *Mol. Pharmacol.* **2006**, 70, 16.
- [18] N. Unwin, *J. Mol. Biol.* **2005**, 346, 967.
- [19] M. Yi, H. Tjong, H. X. Zhou, *Proc. Natl. Acad. Sci. USA* **2008**, 105, 8280.
- [20] P. M. England, Y. Zhang, D. A. Dougherty, H. A. Lester, *Cell* **1999**, 96, 89.
- [21] T. Lu, A. Y. Ting, J. Mainland, L. Y. Jan, P. G. Schultz, J. Yang, *Nat. Neurosci.* **2001**, 4, 239.
- [22] Y. Nagaoka, L. Shang, A. Banerjee, H. Bayley, S. J. Tucker, *ChemBioChem* **2008**, 9, 1725.
- [23] K. R. Gleitsman, J. A. P. Shanata, S. J. Frazier, H. A. Lester, D. A. Dougherty, *Biophys. J.* **2009**, 283, 3168–3178.
- [24] R. Pantoja, E. A. Rodriguez, M. I. Dibas, D. A. Dougherty, H. A. Lester, *Biophys. J.* **2009**, 96, 226.
- [25] S. Nirthanan, M. C. Gwee, *J. Pharmacol. Sci.* **2004**, 94, 1.
- [26] A. Miyazawa, Y. Fujiyoshi, N. Unwin, *Nature* **2003**, 423, 949.
- [27] C. D. Dellisanti, Y. Yao, J. C. Stroud, Z. Z. Wang, L. Chen, *Nat. Neurosci.* **2007**, 10, 953.
- [28] X. Cheng, H. Wang, B. Grant, S. M. Sine, J. A. McCammon, *PLoS Comput. Biol.* **2006**, 2, e134.
- [29] M. W. Nowak, J. P. Gollivan, S. K. Silverman, C. G. Labarca, D. A. Dougherty, H. A. Lester, *Methods Enzymol.* **1998**, 293, 504.

Received: February 20, 2009

Published online on April 29, 2009